"Neumora’s Alzheimer’s disease agitation drug shows early success in Phase Ib trial" was originally created and published by ...

NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect NMRA-511 demonstrated unsurpassed ...

Agitation is a neuropsychiatric symptom in patients with Alzheimer's disease (AD), the most common form of dementia. The prevalence of this symptom is about 40%-65% ...

While most people are familiar with Alzheimer’s disease, a progressive neurological disorder and the most common cause of dementia, it is often difficult to truly understand the common symptoms and ...

New safety study links sedative use to increased stroke risk. A large UK study involving more than 165,000 people with dementia has found that the drug risperidone increases the risk of stroke in all ...

Please provide your email address to receive an email when new articles are posted on . Researchers reviewed 18 randomized clinical trials that recruited individuals with dementia and ...

A large UK study of over 165,000 dementia patients finds risperidone raises stroke risk in all users, prompting concerns over ...

Approximately 6.5 million Americans and their loved ones, friends, and caregivers experience the distress associated with Alzheimer’s dementia. One of the most troubling symptoms associated with this ...

Please provide your email address to receive an email when new articles are posted on . The model, along with a traffic-light system, boosted sensitivity and specificity of agitation recognition.

Combative and agitated behavior in people with dementia is not rare. Managing this behavior is difficult. Research is limited but cannabis may be of help. The concepts of cannabis use in our society ...

In a recent study published in the Journal of the American Geriatrics Society, a group of researchers assessed the longitudinal relationship between chronic, resolved, and new onset anxiety and the ...